Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID ‐19
Cell Proliferation · 2024
DOI: 10.1111/cpr.13617 ↗At a glance
Journal article in Cell Proliferation, 2024. Written by Yifei Zeng and 9 co-authors. Institution: Department of Infectious Diseases, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: COVID-19, Blood Proteins, Proteome, Proteomics. Cited 3 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Binjiang Institute of Zhejiang University, Qianjiang Distinguished Scholar Program from Hangzhou City.
Abstract (original language)
COVID‐19 has been a global concern for 3 years, however, consecutive plasma protein changes in the disease course are currently unclear. Setting the mortality within 28 days of admission as the main clinical outcome, plasma samples were collected from patients in discovery and independent validation groups at different time points during the disease course. The whole patients were divided into death and survival groups according to their clinical outcomes. Proteomics and pathway/network analyses were used to find the differentially expressed proteins and pathways. Then, we used machine learning to develop a protein classifier which can predict the clinical outcomes of the patients with COVID‐19 and help identify the high‐risk patients. Finally, a classifier including C‐reactive protein, extracellular matrix protein 1, insulin‐like growth factor‐binding protein complex acid labile subunit, E3 ubiquitin‐protein ligase HECW1 and phosphatidylcholine‐sterol acyltransferase was determined. The prediction value of the model was verified with an independent patient cohort. This novel model can realize early prediction of 28‐day mortality of patients with COVID‐19, with the area under curve 0.88 in discovery group and 0.80 in validation group, superior to 4C mortality and E‐CURB65 scores. In total, this work revealed a potential protein classifier which can assist in predicting the outcomes of COVID‐19 patients and providing new diagnostic directions.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Infectious Diseases, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Multiple Organ Failure (Zhejiang University), Ministry of Education, Hangzhou, China.
- Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou, China.
ORCID profiles: Feng Xu
Funding
- National Natural Science Foundation of China
- Binjiang Institute of Zhejiang University
- Qianjiang Distinguished Scholar Program from Hangzhou City
Cite
APA
Zeng, Y., Li, Y., Zhang, W., Lu, H., Lin, S., Zhang, W., Xia, L., Hu, H., Song, Y., & Xu, F. (2024). Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID ‐19. Cell Proliferation. https://doi.org/10.1111/cpr.13617
Vancouver
Zeng Y, Li Y, Zhang W, Lu H, Lin S, Zhang W, et al. Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID ‐19. Cell Proliferation. 2024. doi:10.1111/cpr.13617
BibTeX
@article{Zeng2024,
author = {Zeng, Yifei and Li, Yufan and Zhang, Wanying and Lu, Huidan and Lin, Siyi and Zhang, Wenting and Xia, Lexin and Hu, Huiqun and Song, Yuanlin and Xu, Feng},
title = {Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID ‐19},
journal = {Cell Proliferation},
year = {2024},
doi = {10.1111/cpr.13617}
}
EUVIMED